Perrigo must face a lawsuit in the US over its proposed generic to Bausch Health’s Duobrii (halobetasol propionate/tazarotene) lotion for the treatment of plaque psoriasis in adults, the company’s collaboration partner Sol-Gel Technologies has confirmed.
With Perrigo having sent the originator a Paragraph IV patent challenge certification on 23 July, asserting invalidity and/or non-infringement of...






